ZLDPF (Zealand Pharma AS) Cyclically Adjusted Revenue per Share: $2.69 (As of Mar. 2026)


ZLDPF Zealand Pharma AS ZLDPF
63 GF Score
Price $45.29
GF Value $1,896.28
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Cyclically Adjusted Revenue per Share?

Zealand Pharma AS ZLDPF -0.70% 63 Cyclically Adjusted Revenue per Share is $2.69 as of Mar. 2026. GuruFocus rates ZLDPF with a GF Score™ of 63/100 and a GF Value™ of $1,896.28 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zealand Pharma AS's adjusted revenue per share for the three months ended in Mar. 2026 was $0.074. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.69 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zealand Pharma AS's average Cyclically Adjusted Revenue Growth Rate was 253.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 51.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zealand Pharma AS was 51.20% per year. The lowest was -7.60% per year. And the median was -4.45% per year.

As of today (2026-07-08), Zealand Pharma AS's current stock price is $45.29. Zealand Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $2.69. Zealand Pharma AS's Cyclically Adjusted PS Ratio of today is 16.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zealand Pharma AS was 179.43. The lowest was 13.32. And the median was 35.13.


Zealand Pharma AS  (OTCPK:ZLDPF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zealand Pharma AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=45.29/2.69
=16.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zealand Pharma AS was 179.43. The lowest was 13.32. And the median was 35.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zealand Pharma AS Cyclically Adjusted Revenue per Share Related Terms


Zealand Pharma AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Cyclically Adjusted Revenue per Share Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.71 0.83 0.71 2.71

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 2.96 2.84 2.71 2.69

ZLDPF vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Cyclically Adjusted PS Ratio falls into.


ZLDPF
63GF Score
Zealand Pharma AS ZLDPF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.074/121.6800*121.6800
=0.074

Current CPI (Mar. 2026) = 121.6800.

Zealand Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.050 100.600 0.060
201609 0.248 100.200 0.301
201612 0.980 100.300 1.189
201703 0.427 101.200 0.513
201706 0.059 101.200 0.071
201709 0.220 101.800 0.263
201712 0.052 101.300 0.062
201803 0.052 101.700 0.062
201806 0.077 102.300 0.092
201809 0.000 102.400 0.000
201812 0.065 102.100 0.077
201903 0.000 102.900 0.000
201906 0.095 102.900 0.112
201909 0.045 102.900 0.053
201912 0.047 102.900 0.056
202003 0.051 103.300 0.060
202006 0.898 103.200 1.059
202009 0.226 103.500 0.266
202012 -0.395 103.400 -0.465
202103 0.022 104.300 0.026
202106 0.137 105.000 0.159
202109 0.199 105.800 0.229
202112 0.047 106.600 0.054
202203 0.038 109.900 0.042
202206 0.081 113.600 0.087
202209 0.126 116.400 0.132
202212 0.067 115.900 0.070
202303 0.038 117.300 0.039
202306 0.026 116.400 0.027
202309 0.702 117.400 0.728
202312 0.058 116.700 0.060
202403 0.036 118.400 0.037
202406 0.079 118.500 0.081
202409 0.009 118.900 0.009
202412 0.018 118.900 0.018
202503 0.016 120.200 0.016
202506 19.593 120.700 19.752
202509 0.111 121.600 0.111
202512 0.152 121.200 0.153
202603 0.074 121.680 0.074

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.69 mean?
Zealand Pharma AS (ZLDPF) has a Cyclically Adjusted Revenue per Share of $2.69 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Cyclically Adjusted Revenue per Share too high?
Zealand Pharma AS's current Cyclically Adjusted Revenue per Share is $2.69. Overall, Zealand Pharma AS has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Zealand Pharma AS's Cyclically Adjusted Revenue per Share of $2.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Cyclically Adjusted Revenue per Share is $2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,896.28, compared to a current price of $45.29 — trading 97.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.69. Zealand Pharma AS's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Cyclically Adjusted Revenue per Share is $2.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $45.29 is trading 97.6% below its estimated GF Value™ of $1,896.28. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Cyclically Adjusted Revenue per Share: $2.69
  • GF Value™: $1,896.28 vs. price of $45.29 (97.6% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
63GF Score

Get the complete analysis for ZLDPF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.29
Price
$1,896.28
GF Value